Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd is well-positioned for success with its innovative mAb therapies addressing high-need viral infectious diseases. The company's LIBERTY Phase 3 trial presents a compelling opportunity to gather controlled data on VYD2311's safety and tolerability compared to mRNA vaccines, potentially positioning it as a favorable alternative. Additionally, Invivyd's well-designed DECLARATION trial and strong payer and policy feedback suggest a positive commercial outlook for its flagship product.

Bears say

Invivyd is a biopharmaceutical company with a negative outlook as its success is heavily dependent on the success of its lead product, PEMGARDA, and the potential success of its other antibody candidates is uncertain. Additionally, the company's valuation is highly dependent on the risk-adjusted discounted cash flow methodology, with a high risk adjustment for its COVID prophylaxis franchise. The company also faces various risks, including clinical development, competitor, and pricing risks, which could impact its ability to achieve its price target. Moreover, while recent safety updates have been positive, there is still uncertainty around the effectiveness of their monoclonal antibodies against evolving COVID-19 strains, and any unexpected changes could impact the company's future prospects.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.